Bank of America Merrill Lynch 20230420_HORIZON THERAPEUTICS PLC_38.5 (b)_IE_BANA (0779X)
21 Aprile 2023 - 11:50AM
UK Regulatory
TIDMHZNP TIDMTTM
RNS Number : 0779X
Bank of America Merrill Lynch
21 April 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT,
1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED
INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader Bank of America, N.A., Proprietary
Company dealt in HORIZON THERAPEUTICS PLC
-----------------------------------
Class of relevant security to which the Common - IE00BQPVQZ61
dealings being disclosed relate(Note 1)
-----------------------------------
Date of dealing 20/04/2023
-----------------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing)
in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common IE00BQPVQZ61
Long Short
------------------- --------------------
Number % Number %
---------- ------- ---------- --------
(1) Relevant securities 1,536,462 0.672% 394,642 0.173 %
---------- ------- ---------- --------
(2) Derivatives (other than options): 513,066 0.224% 1,557,844 0.681%
---------- ------- ---------- --------
(3) Options and agreements to purchase/sell: 0 0% 0 0%
---------- ------- ---------- --------
Total 2,049,528 0.896% 1,952,486 0.854%
---------- ------- ---------- --------
(b) Interests and short positions in relevant securities
of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long Short
------------ ------------
Number % Number %
------- --- ------- ---
(1) Relevant securities 0 0% 0 0%
------- --- ------- ---
(2) Derivatives (other than options): 0 0% 0 0%
------- --- ------- ---
(3) Options and agreements to purchase/sell: 0 0% 0 0%
------- --- ------- ---
Total 0 0% 0 0%
------- --- ------- ---
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit (Note 4)
Purchase 1 111.92 USD
------------------------------ ------------------------
Purchase 6,500 111.86 USD
------------------------------ ------------------------
Purchase/sale Number of relevant securities Price per unit (Note 4)
Sale 7,680 111.75 USD
------------------------------ ------------------------
Sale 72 111.8 USD
------------------------------ ------------------------
Sale 214 111.76 USD
------------------------------ ------------------------
Sale 52 111.77 USD
------------------------------ ------------------------
Sale 178 111.72 USD
------------------------------ ------------------------
Sale 556 111.74 USD
------------------------------ ------------------------
Sale 32 111.755 USD
------------------------------ ------------------------
Sale 20 111.745 USD
------------------------------ ------------------------
Sale 55 111.78 USD
------------------------------ ------------------------
Sale 30 111.79 USD
------------------------------ ------------------------
Sale 319 111.73 USD
------------------------------ ------------------------
Sale 178 111.71 USD
------------------------------ ------------------------
Sale 26 111.69 USD
------------------------------ ------------------------
Sale 100 111.7 USD
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant securities Price per unit
e.g. CFD (Note 5) (Note 6) (Note 4)
Swaps Increasing a Short Position 6,500 111.865 USD
---------------------------- ------------------------------ ---------------
(c) Options transactions in respect of existing relevant
securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry date Option money paid/ received
name, selling, securities price e.g. American, per unit (Note 4)
e.g. call purchasing, to which European
option varying the option etc
etc. relates (Note
7)
N/A N/A N/A N/A N/A N/A N/A
------------- --------------- --------- ---------------- ------------ ------------------------------
(ii) Exercising
Product name, Number of securities Exercise price per
e.g. call option unit (Note 4)
N/A N/A N/A
---------------------- --------------------
(d) Other dealings (including transactions in respect
of new securities) (Note 3)
Nature or transaction Details Price per unit
(Note 7) (if applicable) (Note 4)
N/A N/A N/A
--------- ---------------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.
None
Is a Supplemental Form 38.5(b) attached? (Note 8) No
Date of disclosure 21/04/2023
Contact name Frank Lui
-----------------------
Telephone number +44207 996 6418
-----------------------
Name of offeree/offeror with which connected AMGEN INC
-----------------------
Nature of connection (Note 9) Advisor to - AMGEN INC
-----------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEEANLFALNDEEA
(END) Dow Jones Newswires
April 21, 2023 05:50 ET (09:50 GMT)
Grafico Azioni Amgen (LSE:0R0T)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Amgen (LSE:0R0T)
Storico
Da Giu 2023 a Giu 2024
